PHARMACOKINETIC DRUG–DRUG INTERACTIONS: PHYSIOLOGICAL CHANGES ARISING FROM CONCURRENT ADMINISTRATION OF MULTIPLE MEDICATIONS
DOI:
https://doi.org/10.55640/Keywords:
pharmacokinetics, drug–drug interactions, CYP450 enzymes, absorption, metabolism, excretion, P-glycoprotein, plasma concentration, renal clearance, therapeutic safetyAbstract
This article explores the mechanisms and clinical implications of pharmacokinetic drug–drug interactions that occur when multiple medications are administered simultaneously. Such interactions influence absorption, distribution, metabolism, and excretion, resulting in altered plasma concentrations, therapeutic effects, or toxicity. The analysis discusses the molecular and physiological determinants of drug interactions, including transporter proteins, metabolic enzyme systems, protein-binding dynamics, and renal clearance mechanisms. Special attention is given to cytochrome P450 isoenzymes, P-glycoprotein modulation, and genetic variability affecting drug disposition. The article also examines high-risk clinical scenarios, factors predisposing patients to interactions, and strategies for prevention and monitoring. Overall, this work clarifies the essential principles of pharmacokinetic interactions and highlights their significance in optimizing safe and effective pharmacotherapy.
Downloads
References
1. Shargel, L., Wu-Pong, S., Yu, A.B.C. Applied Biopharmaceutics and Pharmacokinetics. 7th ed. McGraw-Hill; 2016. pp. 215–242.
2. Rowland, M., Tozer, T.N. Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications. 5th ed. Wolters Kluwer; 2019. pp. 301–328.
3. Benet, L.Z., Hoener, B.A. Changes in Plasma Protein Binding and Their Impact on Pharmacokinetic Drug Interactions. Clinical Pharmacokinetics. 2002;41(15): pp. 1219–1234.
4. Neuvonen, P.J., Niemi, M., Backman, J.T. Drug Interactions With Lipid-Lowering Drugs: Mechanisms and Clinical Relevance. Clinical Pharmacology & Therapeutics. 2006;80(6): pp. 565–581.
5. Patsalos, P.N., Perucca, E. Clinically Relevant Drug Interactions in Epilepsy: General Features and Interactions Between Antiepileptic Drugs. The Lancet Neurology. 2003;2(6): pp. 347–356.
6. Farkas, D., Greenblatt, D.J. Influence of CYP3A Inhibitors and Inducers on the Pharmacokinetics of Common Medications. Journal of Clinical Pharmacology. 2008;48(2): pp. 186–199.
7. Hollenberg, P.F. Characteristics and Common Properties of Inhibitors, Inducers, and Activators of CYP Enzymes. Drug Metabolism Reviews. 2002;34(1–2): pp. 17–35.
8. Wu, C.Y., Benet, L.Z. Predicting Drug Interactions From In Vitro Data: Mechanistic Insights. Pharmaceutical Research. 2005;22(11): pp. 1773–1785.
9. Bonate, P.L. Pharmacokinetic-Pharmacodynamic Modeling and Simulation. Springer; 2011. pp. 98–126.
10. Hansten, P.D., Horn, J.R. Drug Interactions Analysis and Management. Wolters Kluwer; 2020. pp. 45–78.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
Germany
United States of America
Italy
United Kingdom
France
Canada
Uzbekistan
Japan
Republic of Korea
Australia
Spain
Switzerland
Sweden
Netherlands
China
India
